Advertisement

Breast Cancer Risk Assessment and Management of the High-Risk Patient

  • Victoria L. Green
    Correspondence
    Corresponding author: Department of Gynecology and Obstetrics, Glenn Building, 4th Floor, Atlanta, GA 30303.
    Affiliations
    Department of Gynecology and Obstetrics, Emory University, Glenn Building 4th Floor, Atlanta, GA 30303, USA

    Gynecology Comprehensive Breast Center, Winship Cancer Institute at Grady Memorial Hospital

    Avon Breast Center
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • American Cancer Society
        Cancer facts & figures 2021.
        American Cancer Society, Atlanta (GA)2021 (Available at:) (Accessed February 8, 2021)
        • American Cancer Society
        Cancer treatment & survivorship facts & figures 2019-2021.
        American Cancer Society, Atlanta (GA)2019
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer Statistics, 2020.
        CA Cancer J Clin. 2020; 70: 7-30
        • Chlebowski R.T.
        • Rohan T.E.
        • Manson J.E.
        • et al.
        Breast cancer after use o of estrogen plus progestin and estrogen alone: analyses of data from two women’s health initiative randomized clinical trials.
        JAMA Oncol. 2015; 1 (Level I): 296-305
        • Rungruang B.
        • Kelley J.L.
        Benign breast diseases: epidemiology, evaluation, and management.
        Clin Obstet Gynecol. 2011; 54 (Level III): 110-124
        • Lauby-Secretan B.
        • Scoccianti C.
        • Loomis D.
        • et al.
        Body fatness and cancer. Viewpoint of the IARC working group.
        N Engl J Med. 2016; 375: 794-798
        • Green V.L.
        Mammographic breast density and breast cancer risk: Implications of density legislation for practice.
        Clin Obstet Gynecol. 2016; 59: 419-438
        • Bagnardi V.
        • Rota M.
        • Botteri E.
        • et al.
        Light alcohol drinking and cancer: a meta-analysis.
        Ann Oncol. 2013; 24: 301-308
        • Gaudet M.M.
        • Gapstur S.M.
        • Sun J.
        • et al.
        Active smoking and breast cancer risk: original cohort data and meta-analysis.
        J Natl Cancer Inst. 2013; 105: 515-525
        • Pizot C.
        • Boniol M.
        • Mullie P.
        • et al.
        Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies.
        Eur J Cancer. 2016; 52: 138-154
        • Henderson T.O.
        • Amsterdam A.
        • Bhatia S.
        • et al.
        Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer.
        Ann Intern Med. 2010; 152 (W144-455. (Systematic Review)): 444-455
        • Bhatia S.
        • Yasui Y.
        • Robison L.L.
        • et al.
        High risk of subsequent neoplasms continues with extended follow up of childhood Hodgkin’s disease: report from the Late Effects Study Group.
        J Clin Oncol. 2003; 21: 4386-4394
      1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. Version 1.2020.
        (Available at:) (Accessed February 15, 2021)
      2. Collaborative group on hormonal factors in breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without disease.
        Lancet. 2002; 360: 187-195
        • Chowdhury R.
        • Sinha B.
        • Sankar M.J.
        • et al.
        Breastfeeding and maternal health outcomes: a systematic review and meta-analysis.
        Acta Paediatr. 2015; 104: 96-113
        • Goncalves A.K.
        • Dantas Florencio G.L.
        • Maisonnette de Atayde Silva M.J.
        • et al.
        Effects of physical activity on breast cancer prevention: a systematic review.
        J Phys Act Health. 2014; 11: 445-454
        • Noone A.M.
        • Howlander N.
        • Krapcho M.
        • et al.
        SEER cancer statistics review, 1975-2015.
        National Cancer Institute, Bethesda (MD)2018 (Available at:) (based on November 2017 SEER data submission)
        • American Cancer Society
        Cancer facts & figures for African Americans 2019-2021.
        American Cancer Society, Atlanta (GA)2019: 12
        • McCarthy A.M.
        • Kim J.J.
        • Beaber E.F.
        • et al.
        Follow –up of abnormal breast and colorectal cancer screening by race/ethnicity.
        Am J Prev Med. 2016; 51: 507-512
        • Selove R.
        • Kilbourne B.
        • Fadden M.K.
        • et al.
        Time from screening mammography to biopsy and from biopsy to breast cancer treatment among black and white women Medicare beneficiaries not participating in a health maintenance organization.
        Womens Health Issues. 2016; 26: 642-647
        • Jemal A.
        • Robbins A.S.
        • Lin C.C.
        • et al.
        Factors that contributed to black-white disparities in survival among nonelderly women with breast cancer between 2004 and 2013.
        J Clin Oncol. 2018; 36: 14-24
        • Danforth JR., D.N.
        Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors.
        Breast Cancer Res. 2013; 15: 208
        • Ellis L.
        • Canchola A.J.
        • Spiegel D.
        • et al.
        Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional and neighborhood characteristics.
        J Clin Oncol. 2018; 36: 25-33
        • Singh G.K.
        • Jemal A.
        Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities.
        J Environ Public Health. 2017; 2017: 2819372
        • Committee on lesbian, gay, bisexual and transgender health issues and research gaps and opportunities, board of the health of select populations
        • Institute of Medicine
        The health of lesbian, gay, bisexual and transgender people: building a foundation for better understanding.
        National Academies Press, Washington, DC2011
        • Malone J.
        • Snguon S.
        • Dean L.T.
        • et al.
        Breast cancer screening and care among black sexual minority women: a scoping review of the literature from 1990 to2017.
        J Womens Health. 2019; 28: 1650-1660
      3. Collaborative group on hormonal factors in breast cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58.209 women with breast cancer and 101,986 women without the disease.
        Lancet. 2001; 358: 1389-1399
        • Green V.L.
        Breast Diseases: Benign and Malignant.
        in: Rock J.A. Jones III, H.W. TeLinde’s Operative Gynecology. 10th edition. Lippincott Williams & Wilkins, Philadelphia2008
        • Nelson H.D.
        • Fu R.
        • Zakher B.
        • et al.
        Medication use to reduce risk of breast cancer US Preventive Services task force recommendation statement.
        JAMA. 2019; 322: 857-867
        • Gail M.H.
        • Mai P.L.
        Comparing breast cancer risk assessment models.
        J Natl Cancer Inst. 2010; 102: 665-668
        • Madigan M.R.
        • Ziegler R.G.
        • Benichou J.
        • et al.
        Proportion of breast cancer cases in the United States explained by well-established risk factors.
        J Natl Cancer Inst. 1995; 87: 1681-1685/
        • McCullough M.L.
        • Feigelson H.S.
        • Diver W.R.
        • et al.
        Risk factors for fatal breast cancer in African American women and white women in a large US prospective cohort.
        Am J Epidemiol. 2005; 162: 734-742
        • Antoniou A.
        • Pharoah P.D.
        • Narod S.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
        Am J Hum Genet. 2003; 72: 1117-1130
        • Tung N.
        • Domchek S.M.
        • Stadler Z.
        • et al.
        Counselling framework for moderate penetrance cancer susceptibility mutations.
        Nat Rev Clin Oncol. 2016; 13: 581-588
        • Ray J.A.
        • Loescher L.J.
        • Brewer M.
        Risk-reduction surgery decisions in high-risk women seen for genetic counseling.
        J Gen Couns. 2005; 14: 473-484
        • Sutherland S.
        • Meiser B.
        • Kaur R.
        • et al.
        Assessing the medical workforces perceived barriers to the prescription of risk-reducing medication for women at high-risk of breast cancer.
        Breast J. 2019; 25: 34-40
        • Maas P.
        • Barrdahl M.
        • Joshi A.D.
        • et al.
        Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States.
        JAMA Oncol. 2016; 2: 1295-1302
        • Song M.
        • Giovannucci E.
        Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States.
        JAMA Oncol. 2016; 2: 1154-1161
        • Mahoney M.C.
        • Bevers T.
        • Linos E.
        • et al.
        Opportunities and strategies for breast cancer prevention through risk reduction.
        CA Cancer J Clin. 2008; 58: 347-371
        • Chen W.Y.
        • Rosner B.
        • Hankingon S.E.
        • et al.
        Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk.
        JAMA. 2011; 306: 1884-1890
      4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. Version 1.2020.
        (Available at:) (Accessed November 23, 2020)
        • Bernstein L.
        • Patel V.
        • Ursin G.
        • et al.
        Lifetime recreational exercise activity and breast cancer risk among black women and white women.
        J Natl Cancer Inst. 2005; 97: 1671-1679
        • Neihoff N.M.
        • White A.J.
        • Sandler D.P.
        Childhood and teenage physical activity and breast cancer risk.
        Breast Cancer Res Treat. 2017; 164: 697-705
        • Boeke C.E.
        • Eliassen A.H.
        • Oh H.
        • et al.
        Adolescent physical activity in relation to breast cancer risk.
        Breast Cancer Res Treat. 2014; 145: 715-724
        • Howard R.A.
        • Leitzmann M.F.
        • Linet M.S.
        • et al.
        Physical activity and breast cancer risk among pre- and postmenopausal women in the U.S. Radiologic Technologists cohort.
        Cancer Causes Control. 2009; 20: 323-333
        • Calle E.E.
        • Rodriguez C.
        • Walker-Thurmond K.
        • et al.
        Overweight, obesity, and mortality from cancer in a prospectively studies cohort of US adults.
        J Engl J Med. 2002; 348: 1625-1638
        • Bruning P.F.
        • Bonfrer J.M.
        • van Noord P.A.
        • et al.
        Insulin resistance and breast cancer risk.
        Int J Cancer. 1992; 52: 511-516
        • Talamini R.
        • Franceschi S.
        • Favero A.
        • et al.
        Selected medical conditions and risk of breast cancer.
        Br J Cancer. 1997; 75: 1699-1703
        • Eliassen A.H.
        • Colditz G.A.
        • Rosner B.
        • et al.
        Adult weight change and risk of postmenopausal breast cancer.
        JAMA. 2006; 296: 193-201
        • Farvid M.S.
        • Chen W.Y.
        • Michels K.B.
        • et al.
        Fruit and vegetable consumption in adolescence and early adulthood and risk of breast cancer: population based cohort study.
        BMJ. 2016; 353: i2343
        • Linos E.
        • Willett W.C.
        Diet and breast cancer risk reduction.
        J Natl Compr Canc Netw. 2007; 5: 711-718
        • Dong J.Y.
        • Qin L.Q.
        Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies.
        Breast Cancer Res Treat. 2011; 125: 315-323
        • Zhou Y.
        • Chen J.
        • Li Q.
        • et al.
        Association between breastfeeding and breast cancer risk: evidence from a meta-analysis.
        Breastfeed Med. 2015; 10: 175-182
        • Palmer J.R.
        • Boggs D.A.
        • Wise L.A.
        • et al.
        Parity and lactation in relation to estrogen reception negative breast cancer in African American women.
        Cancer Epidemiol Biomarkers Prev. 2011; 20: 1883-1891
        • Green V.L.
        • Killings N.L.
        • Clare C.A.
        The historical, psychosocial, and cultural context of breastfeeding in the African American community.
        Breastfeed Med. 2021; 16: 1-5
      5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer risk reduction. Version 1.2020.
        (Available at:) (Accessed February 1, 2021)
        • Visvanathan K.
        • Fabian C.J.
        • Bantug E.
        • et al.
        Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline.
        J Clin Oncol. 2019; 37: 3152-3165
        • DeCensi A.
        • Gandini S.
        • Serrano D.
        • et al.
        Randomized dose ranging trial of tamoxifen in low doses in hormone replacement therapy users.
        J Clin Oncol. 2007; 25: 4201-4209
        • Freedman A.N.
        • Yu B.
        • Gail M.H.
        • et al.
        Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
        J Clin Oncol. 2011; 29: 2327-2333
        • Fisher B.
        • Costantino J.P.
        • Wickerham D.L.
        • et al.
        Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
        J Natl Cancer Inst. 1998; 90: 1371-1388
        • Cuzick J.
        • Forbes J.
        • Edwards R.
        • et al.
        First results from the International Breast Cancer Intervention Study (IBIS-1) a randomized prevention trial.
        Lancet. 2002; 360: 817-824
        • Cuzick
        • Forbes J.F.
        • Sestak I.
        • et al.
        Long-term results of tamoxifen prophylaxis for breast cancer – 96 month follow up of the randomized IBIS-1 trial.
        J Natl Cancer Inst. 2007; 99: 272-282
        • Cuzick J.
        • Sestak I.
        • Cawthorn S.
        • et al.
        IBIS-I Investigators. Tamoxifen for prevention of breast cancer: extended long –term follow-up of the IBIS-I breast cancer prevention trial.
        Lancet Oncol. 2015; 16: 67-75
        • Powles T.J.
        • Eeles R.
        • Ashley S.
        Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial.
        Lancet. 1998; 352: 98-101
        • Powles T.J.
        • Ashley S.
        • Tidy A.
        • et al.
        Twenty-year follow up of the Royal Marsden randomized, double –blinded tamoxifen breast cancer prevention trial.
        J Natl Cancer Inst. 2007; 99: 283-290
        • Veronesi U.
        • Maisonneuve P.
        • Costa A.
        • et al.
        Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Italian tamoxifen prevention study.
        Lancet. 1998; 352: 93-97
        • Veronesi U.
        • Maisonneuve P.
        • Rotmensz N.
        • et al.
        Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy.
        J Natl Cancer Inst. 2007; 99: 727-737
        • Veronesi U.
        • Maisonneuve P.
        • Rotmensz N.
        • et al.
        Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high risk women.
        J Natl Cancer Inst. 2003; 95: 160-165
        • Cummings S.R.
        • Eckert S.
        • Krueger K.A.
        • et al.
        The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation.
        JAMA. 1999; 281: 2189-2197
        • Martino S.
        • Cauley J.A.
        • Barrett-Connor E.
        • et al.
        Continuing outcomes relevant to evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
        J Natl Cancer Inst. 2004; 96: 1751-1761
        • Grady D.
        • Cauley J.A.
        • Geiger M.F.
        • et al.
        Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
        J Natl Cancer Inst. 2008; 100: 854-861
        • Vogel V.G.
        • Costantino J.P.
        • Wickerham D.L.
        • et al.
        Update of the national Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P2 trial: Preventing breast cancer.
        Cancer Prev Res. 2010; 3: 696-706
        • Wickerham D.L.
        • fisher B.
        • Wolmark N.
        • et al.
        Association of tamoxifen and uterine sarcoma.
        J Clin Oncol. 2002; 20: 4403
        • DeCensi A.
        • Putoni M.
        • Guerrieri-Gonzaga A.
        • et al.
        Randomized placebo controlled trial of low dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia.
        J Clin Oncol. 2019; 37: 1629-1637
        • Land S.R.
        • Wickerham D.L.
        • Costantino J.R.P.
        • et al.
        Patient-reported symptoms and quality of life during treatment of tamoxifen and Raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
        JAMA. 2006; 295: 2742-2751
        • Cuzick J.
        • DeCensi a.
        • Banu A.
        • et al.
        preventive therapy for breast cancer: a consensus statement.
        Lancet. 2011; 12: 496-503
        • Narod S.A.
        • Brunet J.S.
        • Ghadirian P.
        • et al.
        Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Hereditary Breast Cancer Clinical Study Group.
        Lancet. 2000; 356: 1876-1881
        • Baum M.
        • Budzar A.U.
        • Cuzick J.
        • et al.
        Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial.
        Lancet. 2002; 359: 2131-2139
        • Baum M.
        • Budzar A.U.
        • Cuzick J.
        • et al.
        Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC Arimidex, Tamoxifen Alone or in Combination: trial efficacy and safety update analyses.
        Cancer. 2003; 98: 1802-1810
        • Coombes R.C.
        • Hall E.
        • Gibson L.J.
        • et al.
        A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
        N Engl J Med. 2004; 350: 1081-1092
        • Goss P.E.
        • Ingle J.N.
        • Martino S.
        • et al.
        A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
        N Engl J Med. 2003; 349: 1793-1802
        • Thurlimann B.
        • Keshaviah A.
        • Coates A.S.
        • et al.
        A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
        N Engl J Med. 2005; 353: 2747-2757
        • Goss P.E.
        • Ingle J.N.
        • Ales-Martinez J.E.
        • et al.
        Exemestane for breast cancer prevention in postmenopausal.
        N Engl J Med. 2011; 364: 2381-2391
        • Cuzick J.
        • Sestak I.
        • Forbes J.F.
        • et al.
        Anastrozole for prevention of breast cancer in high risk postmenopausal women (IBISII): an international, double blind, randomized placebo controlled trial.
        Lancet. 2014; 383: 1041-1048
        • Nemati Shafaee M.
        • Gutierrez-Barrera A.M.
        • Lin H.Y.
        • et al.
        Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers.
        J Clin Oncol. 2015; 33: 3-13
        • Cheung A.M.
        • Tile L.
        • Cardew S.
        • et al.
        Bone density and structure in healthy postmenopausal women treated with Exemestane for the primary prevention of breast cancer: a nested substudy of the MAP 3 randomised controlled trial.
        Lancet Oncol. 2012; 13: 275-284
        • Yang Z.
        • Simondsen K.
        • Kolesar J.
        Exemestane for primary prevention of breast cancer in postmenopausal women.
        Am J Health Syst Pharm. 2012; 69: 1384-1388
        • Visvanathan K.
        • Lippman S.M.
        • Hurley P.
        • et al.
        American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including Tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
        Gynecol Oncol. 2009; 115: 132-134
        • Nelson H.D.
        • Fu R.
        • Zakher B.
        • et al.
        Medication use for the risk reduction of primary breast cancer in women: a systematic review for the U.S. preventive services task force.
        Agency for Healthcare Research and Quality, Rockville (MD)2019
        • Sideras K.
        • Ingle J.N.
        • Amer M.M.
        • et al.
        Coprescription of tamoxifen and medications that inhibit CYP2D6.
        J Clin Oncol. 2010; 28: 2768-2776
        • Lash T.L.
        • Rosenberg C.L.
        Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.
        J Clin Oncol. 2010; 28: 1273-1275
        • Nelson H.D.
        • Fu R.
        • Zakher B.
        • et al.
        Medication use for the risk reduction of primary breast cancer women: updated evidence report and systematic review for the US Preventive Services task force.
        JAMA. 2019; 322: 868-886
        • Pruthi S.
        • Heisey R.E.
        • Bevers T.B.
        Chemoprevention for breast cancer.
        Ann Surg Oncol. 2015; 22: 3230-3235
        • Forbes J.F.
        • Sestak I.
        • Howell A.
        • et al.
        IBIS-II investigators. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomized controlled trial.
        Lancet. 2016; 387: 866-873
        • Goldvaser H.
        • Barnes T.A.
        • Seruga B.
        • et al.
        Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis.
        J Natl Cancer Inst. 2018; 110https://doi.org/10.1093/jnci/djx141
      6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis. Version 1.2020.
        (Available at:) (Accessed February 1, 2021)
        • Port E.R.
        • Park A.
        • Borgen P.I.
        • et al.
        Results of MRI screening for breast cancer in high risk patients with LCIS and atypical hyperplasia.
        Ann Surg Oncol. 2007; 14: 1051-1057
        • American Cancer Society
        Breast cancer facts & figures 2019-2021.
        American Cancer Society, Inc, Atlanta (GA)2019
        • Smith R.A.
        • Saslow D.
        • Sawyer K.A.
        • et al.
        American Cancer Society guidelines for breast cancer screening: update 2003.
        CA Cancer J Clin. 2003; 53: 141-169
        • Coates R.J.
        • Uhler R.J.
        • Brogan D.J.
        • et al.
        Patterns and predictors of the breast cancer detection methods in women under age 45 years of age (United States).
        Cancer Causes Control. 2001; 12: 431-442
        • Newcomer L.
        • Mewcomb P.
        • Trentham-Dietz A.
        • et al.
        Detection method and breast carcinoma histology.
        Cancer. 2002; 95: 470-477
        • Shen Y.
        • Zelen M.
        Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations.
        J Clin Oncol. 2001; 19: 3490-3499
        • Kosters J.P.
        • Gotzsche P.C.
        Regular self-examination or clinical examination early detection of breast cancer.
        Cochrane Database Syst Rev. 2003; : CD003373
        • Barton M.B.
        • Harris R.
        • Fletcher S.W.
        The rational clinical examination. Does this patient have breast cancer: The screening clinical breast examination: should it be done: How.
        JAMA. 1999; 282: 1270-1280
      7. Breast cancer risk assessment and screening in average risk women. Practice Bulletin No. 179. American College of Obstetricians and Gynecologists.
        Obstet Gynecol. 2017; 130: e1-e16
        • Pisani P.
        • Parkin D.M.
        • Ngelangel C.
        • et al.
        Outcome of screening by clinical examination of the breast in a trial in the Philippines.
        Int J Cancer. 2006; 118: 149-154
      8. Hereditary cancer syndromes and risk assessment. ACOG Committee Opinion No. 793. American College of Obstetricians and Gynecologists.
        Obstet Gynecol. 2019; 134: e143-e149
        • Humphrey L.L.
        • Helfand M.
        • Chan B.K.
        • et al.
        Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force.
        Ann Intern Med. 2002; 137: 347-360
        • Hendrick R.E.
        • Helvie M.A.
        • Monticciolo D.L.
        Breast cancer mortality rates have stopped declining in U.S. women younger than 40 years.
        Radiology. 2021; 00: 1-7
        • Johnson R.H.
        • Anders C.K.
        • Litton J.K.
        • et al.
        Breast cancer in adolescents and young adults.
        Pediatr Blood Cancer. 2018; 65: e27397
        • Carlos R.C.
        • Fendrick A.M.
        • Kolenic G.
        • et al.
        Breast screening utilization and cost sharing among employed insured women after the Affordable Care Act.
        J Am Coll Radiol. 2019; 16: 788-796
        • Ruddy K.J.
        • Gelber S.
        • Tamimi R.M.
        • et al.
        Breast cancer presentation and diagnostic delays in young women.
        Cancer. 2014; 120: 20-25
        • Berg W.A.
        Tailored supplemental screening for breast cancer: what now and what next?.
        AJR Am J Roentgenol. 2009; 192: 390-399
        • Warner E.
        • Messersmith H.
        • Causer P.
        • et al.
        Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.
        Ann Intern Med. 2008; 148: 671-679
        • Saslow D.
        • Boetes C.
        • Burke W.
        • et al.
        American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
        CA Cancer J Clin. 2007; 57: 75-89
        • McDonald R.J.
        • McDonald J.S.
        • Kallmes D.F.
        • et al.
        Gadolinium deposition in human brain tissues after contrast enhanced MR imaging in adult patients without intracranial abnormalities.
        Radiology. 2017; 285: 546-554
        • Darrah T.H.
        • Prutsman-Pfeiffer J.J.
        • Poreda R.J.
        • et al.
        Incorporation of excess gadolinium into human bone from medical contrast agents.
        Metallomics. 2009; 1: 479-488
      9. FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue issued on May 22, 2017. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-body. Accessed 1/6/22

        • Lord S.J.
        • Lei W.
        • Craft P.
        • et al.
        A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer.
        Eur J Cancer. 2007; 43: 1905-1917
        • Leach M.O.
        • Boggis C.R.
        • Kixon A.K.
        • et al.
        Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast can: a prospective multicenter cohort study (MARIBS).
        Lancet. 2005; 365: 1769-1778
        • Mann R.M.
        • Kuhl C.K.
        • Kindel K.
        • et al.
        Breast MRI: guidelines from the European Society of Breast Imaging.
        Eur Radiol. 2008; 18: 1307-1318
        • Kuhl C.K.
        • Keulers A.
        • Strobel K.
        • et al.
        Not all false positive diagnoses are equal: On the prognostic implications of false-positive diagnoses made in breast MRI versus in mammography/digital tomosynthesis screening.
        Breast Cancer Res. 2018; 20: 13-21
        • Niklason L.T.
        • Christia B.T.
        • Niklason L.E.
        • et al.
        Digital tomosynthesis in breast imaging.
        Radiology. 1997; 205: 399-406
        • Caumo F.
        • Bernardi D.
        • Ciatto S.
        • et al.
        Incremental effect from integrating 3D mammography (tomosynthesis) with 2D mammography: increased breast cancer detection evident for screening centres in population based trial.
        Breast. 2014; 23: 76-80
        • Mainiero M.B.
        • Moy L.
        • Baron P.
        • et al.
        ACR appropriateness criteria breast cancer screening.
        ACR. 2017; 14: s383-s392
        • Zuley M.L.
        • Bandos A.I.
        • Abrams G.S.
        • et al.
        contrast enhanced digital mammography (CEDM) health to safely reduce benign breast biopsies for low to moderately suspicious soft tissue lesions.
        Acad Radiol. 2020; 27: 969-976
        • Sorin V.
        • Yagil Y.
        • Shalmon A.
        • et al.
        Background parenchymal enhancement at contrast enhanced spectral mammography (CESM) as a breast cancer risk factor.
        Acad Radiol. 2020; 27: 1234-1240
        • Carbine N.E.
        • Lostumbo L.
        • Wallace J.
        • et al.
        Risk-reducing mastectomy for the prevention of primary breast cancer (review).
        Cochrane Database Syst Rev. 2018; 4
        • Baildam A.D.
        Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms.
        Breast. 2019; 46: 48-51
        • Evans D.G.
        • Baildam A.D.
        • Anderson E.
        • et al.
        Risk reducing mastectomy outcomes in 10 European Centres.
        J Med Genet. 2009; 46: 354-358
        • Heemskerk-Gerritsen B.A.M.
        • Seynaeve C.
        • van Asperen C.J.
        • et al.
        Breast cancer risk after salpingo-oophorectomy in healthy BRCA 1/2 mutation carriers: revisiting the evidence for risk reduction.
        J Natl Cancer Inst. 2015; 107
        • Chapman J.S.
        • Powell C.B.
        Surveillance of survivors: follow up after risk reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers.
        Gynecol Oncol. 2011; 122: 339-343
      10. Opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention. ACOG Committee Opinion No. 774. American College of Obstetricians and Gynecologists.
        Obstet Gynecol. 2019; 133: e279-e284